See more : Nagreeka Exports Limited (NAGREEKEXP.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Acceleron Pharma Inc. (XLRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acceleron Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- e-Direct Inc. (EDZR) Income Statement Analysis – Financial Results
- Quantum FinTech Acquisition Corporation (QFTA) Income Statement Analysis – Financial Results
- Topcon Corporation (TOPCF) Income Statement Analysis – Financial Results
- PT Berlian Laju Tanker Tbk (BLTA.JK) Income Statement Analysis – Financial Results
- Dolphin Offshore Enterprises (India) Limited (DOLPHINOFF.BO) Income Statement Analysis – Financial Results
Acceleron Pharma Inc. (XLRN)
About Acceleron Pharma Inc.
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 173.92M | 153.95M | 103.90M | 89.73M | 68.58M | 58.40M | 50.90M | 36.05M | 35.32M | 32.71M |
| General & Administrative | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Other Expenses | 85.91M | 56.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 40.86M |
| Cost & Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 42.36M |
| Interest Income | 2.87M | 10.71M | 5.57M | 2.55M | 1.85M | 512.00K | 83.00K | 39.00K | 91.00K | 17.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 922.00K | 2.09M | 1.53M | 1.82M |
| Depreciation & Amortization | 3.85M | 3.94M | 3.75M | 2.83M | 1.68M | 1.18M | 1.12M | 915.00K | 1.29M | 3.13M |
| EBITDA | -162.16M | -120.98M | -115.15M | -105.60M | -55.31M | -62.72M | -49.22M | -18.89M | -29.76M | 41.22M |
| EBITDA Ratio | -175.27% | -163.50% | -823.04% | -783.30% | -199.18% | -346.57% | -336.38% | -33.01% | -195.10% | 50.95% |
| Operating Income | -167.31M | -136.45M | -124.41M | -109.98M | -66.11M | -60.88M | -50.46M | 6.95M | -28.89M | 38.56M |
| Operating Income Ratio | -180.83% | -184.40% | -889.24% | -815.84% | -238.04% | -336.40% | -344.89% | 12.15% | -189.39% | 47.65% |
| Total Other Income/Expenses | 1.30M | 11.53M | 5.52M | 1.56M | 9.12M | -3.02M | -795.00K | -28.85M | -3.69M | -2.29M |
| Income Before Tax | -166.01M | -124.92M | -118.90M | -108.42M | -56.99M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Income Before Tax Ratio | -179.42% | -168.83% | -849.82% | -804.26% | -205.21% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| Income Tax Expense | 21.00K | -62.00K | -27.00K | 32.00K | 24.00K | -3.02M | 127.00K | -26.76M | -2.16M | -468.00K |
| Net Income | -166.03M | -124.86M | -118.87M | -108.45M | -57.01M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Net Income Ratio | -179.45% | -168.74% | -849.62% | -804.50% | -205.30% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| EPS | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.73 |
| EPS Diluted | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.58 |
| Weighted Avg Shares Out | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 20.95M |
| Weighted Avg Shares Out (Dil) | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 22.97M |
Merck to buy Acceleron for about $11.5 billion in rare disease drugs push
Merck to Acquire Acceleron Pharma Inc.
Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
The Wall Street Journal: Merck nears deal for rare-disease-drug maker Acceleron
Merck nears deal to acquire Acceleron Pharma
Bristol-Myers Reportedly Most Likely Buyer of Acceleron Pharma
Merck in advanced talks to buy Acceleron Pharma
Acceleron's stock gains 3.9% on acquisition report
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Source: https://incomestatements.info
Category: Stock Reports